All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
On 2nd August 2017, in Histopathology, Victoria Alegría-Landa from Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain, et al. published a case report of a Caucasian male, 81 years of age, with Cutaneous Natural Killer (NK)/T-cell Intravascular Lymphoma (IVL).
IVL is rare and the majority of cases are a type of extranodal Diffuse Large B-Cell Lymphoma (DLBCL). Less than 10% of reported cases are of T-cell origin. This current case of cutaneous NK/T-cell IVL with cytotoxic immunophenotype and EBV positivity is the first triple negative (TCR-βF1, TCR-γ, and CD56) case to be described. This entity has not yet been classified by the World Health Organization and the authors urge that is should be considered as a distinct subtype in future classifications.
Intravascular lymphoma (IVL) is a rare entity. Most cases are a variant of extranodal diffuse large B-cell lymphoma, and fewer than 10% of the published cases are of T-cell origin. Only intravascular B-cell lymphoma is recognized as a distinct entity in the most recent WHO classification of lymphoproliferative disorders. We describe a case of cutaneous NK/T IVL, with a cytotoxic immunophenotype and EBV positivity. However, our case was immunohistochemically negative not only for TCR-βF1 and TCR-γ (TCR-silent), but also for CD56, making it the first triple-negative NK/T IVL case to be described. We urge the recognition of this NK/T-cell lineage intravascular lymphoma due to its particular immunophenotypic profile and its unvarying relationship with EBV. Its occurrence should not be considered a coincidence, but rather a key aspect of the pathogenic background of this haematological neoplasm.
References